[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529810":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":95,"collaborators":19,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":19,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":19,"enrollmentInfo":106,"targetDuration":19,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JNJ-87890387","EXPERIMENTAL","In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.",[13],"Drug: JNJ-87890387",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","JNJ-87890387 will be administered.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[31,45,55,66,75,86],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":19},"Start Midwest","RECRUITING","Grand Rapids","Michigan","49546","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-85.66809,42.96336,{"lat":43,"lon":42},{"facility":46,"status":33,"city":47,"state":48,"zip":49,"country":37,"countryCode":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":19},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":40,"coordinates":51},[52,53],-86.78444,36.16589,{"lat":53,"lon":52},{"facility":56,"status":33,"city":57,"state":19,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":19},"Centre Leon Berard","Lyon","69008","France","FR",{"type":40,"coordinates":62},[63,64],4.84789,45.74906,{"lat":64,"lon":63},{"facility":67,"status":33,"city":68,"state":19,"zip":69,"country":59,"countryCode":60,"cosmosGeoPoint":70,"geoPoint":74,"contacts":19},"Institut Gustave Roussy","Villejuif","94805",{"type":40,"coordinates":71},[72,73],2.35992,48.7939,{"lat":73,"lon":72},{"facility":76,"status":33,"city":77,"state":19,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":19},"Hosp Univ Vall D Hebron","Barcelona","08035","Spain","ES",{"type":40,"coordinates":82},[83,84],2.15899,41.38879,{"lat":84,"lon":83},{"facility":87,"status":33,"city":88,"state":19,"zip":89,"country":79,"countryCode":80,"cosmosGeoPoint":90,"geoPoint":94,"contacts":19},"Hosp. Univ. 12 de Octubre","Madrid","28041",{"type":40,"coordinates":91},[92,93],-3.70256,40.4165,{"lat":93,"lon":92},{"type":96,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100529810","phase-1-a-study-of-jnj-87890387-for-advanced-solid-tumors-100529810",false,"NCT06178614","A Study of JNJ-87890387 for Advanced Solid Tumors","A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase\u002FPhosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) Renal cell cancer (RCC)-clear cell or papillary carcinoma; b) Endometrioid ovarian cancer c) Endometrioid uterine carcinoma; d) Colorectal adenocarcinoma (CRC); e) Lung adenocarcinoma\n* Have measurable or evaluable disease: Part 1- Either measurable or evaluable disease; Part 2- At least 1 measurable lesion per RECIST v1.1. Participants with ovarian cancer without a measurable lesion must have disease evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or have cancer antigen (CA) 125 greater than (\\>) 2\\*upper limit of normal (ULN) during screening\n* All participants in Part 1 and Part 2 must consent to provide an archived tumor tissue sample at screening\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening\n* Be willing and able to adhere to the lifestyle restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Active Central Nervous System (CNS) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \\> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \\[\\\u003C=\\]10 milligrams \\[mg\\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment\n* Toxicity from prior anticancer therapy that has not resolved to Grade \\\u003C=1 (except alopecia, vitiligo, Grade \\\u003C=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement)\n* History of Grade greater than or equal to (\\>=) 2 immune-related AE(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of Grade 2 and Grade 3 immune-related AEs that responded to treatment and that did not recur following rechallenge. Endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed.\n* History of solid organ or hematologic stem cell transplantation\n* Any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment","ALL","18 Years",{"count":107,"type":108},200,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).",[114,115],"Neoplasms","Advanced Solid Tumors","2026-06-04",{"date":118,"type":119},"2026-06-05","ACTUAL",{"date":121,"type":119},"2023-12-14",{"date":123,"type":108},"2029-02-07",{"name":5,"class":6},6]